Vancouver-based company SaNOtize, co-founded by Israeli-Canadian scientist Dr. Gilly Regev, is launching its first clinical trial in the UK this week for a proposed antiviral nasal spray for use against COVID-19.
Lab tests on the SaNOtize treatment at Utah State University’s Antiviral Research Institute confirmed that the company’s Nitric Oxide Releasing Solution inactivated more than 99.9% of SARs-CoV-2, the virus that causes Covid-19, within two minutes.
The SaNOtize treatment is based on nitric oxide, a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes Covid-19. The treatment can be delivered by nasal spray, throat gargle or nasal lavage.
Furthermore, studies using the spray in Covid-19 infected rodents showed a 95% drop in viral load within a day after infection while half the rodents showed no detectable virus.
The rodents were first inoculated with the virus and given two treatments of the nasal spray.
Separate trials have shown that the solution was effective in lab conditions against viruses such as influenza A, hCoV-OC43 and H1N1 (swine flu)
Lab tests on the SaNOtize treatment at Utah State University’s Antiviral Research Institute confirmed that the company’s Nitric Oxide Releasing Solution inactivated more than 99.9% of SARs-CoV-2, the virus that causes Covid-19, within two minutes.
The SaNOtize treatment is based on nitric oxide, a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes Covid-19. The treatment can be delivered by nasal spray, throat gargle or nasal lavage.
Furthermore, studies using the spray in Covid-19 infected rodents showed a 95% drop in viral load within a day after infection while half the rodents showed no detectable virus.
The rodents were first inoculated with the virus and given two treatments of the nasal spray.
Separate trials have shown that the solution was effective in lab conditions against viruses such as influenza A, hCoV-OC43 and H1N1 (swine flu)
